Accession Number:

ADA625990

Title:

Intravesical NGF Antisense Therapy Using Lipid Nanoparticle for Interstitial Cystitis

Descriptive Note:

Annual rept. 30 Sep 2014-29 Sep 2015

Corporate Author:

LIPELLA PHARMACEUTICALS INC PITTSBURGH PA

Report Date:

2015-10-01

Pagination or Media Count:

68.0

Abstract:

Interstitial cystitisbladder pain syndrome ICBPS is a debilitating disorder characterized by persistent pelvic pain associated with bladder symptoms including urinary frequency and urgency. Previous studies have indicated that overexpression of nerve growth factor NGF is a important factor in the symptom development of ICBPS. This project evaluates the feasibility of an anti-NGF bladder drug delivery system as a potential investigational drug product. The project aims include exploration, manufacture, characterization, and nonclinical animal testing of a liposome NGF-antisense formulation targeting ICBPS. During the project period investigators conducted nonclinical experiments and analyzed results from an animal efficacy experiment conducted during the previous period. The project is ongoing.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE